Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | PTGES | O14684 | 1/20 | 0.47 |
| ▸ | LIPE | Q05469 | 3/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2234591 | 0.94 | L3MBTL1 (0.48) | L3MBTL1LMNAPTGESLIPETDP1 | |
| SCHEMBL2234801 | 0.90 | PTGES (0.56) | L3MBTL1PTGESTDP1ATMNPSR1 | |
| SCHEMBL27842386 | 0.86 | HSD17B1 (0.44) | L3MBTL1LMNANPSR1KMT2AMEN1 | |
| SCHEMBL2237040 | 0.82 | PTGES (0.48) | L3MBTL1PTGESTDP1ATMNPSR1 | |
| SCHEMBL2236294 | 0.82 | ATM (0.47) | L3MBTL1LMNALIPEATMTAAR1 | |
| SCHEMBL2236288 | 0.81 | PTGES (0.47) | L3MBTL1PTGESLIPETDP1ATM | |
| SCHEMBL27859909 | 0.80 | MTNR1A (0.47) | L3MBTL1PTGESTDP1ATMKMT2A | |
| SCHEMBL28793433 | 0.77 | PTGES (0.44) | L3MBTL1PTGESTDP1ATMTAAR1 | |
| SCHEMBL2233608 | 0.76 | ALDH1A1 (0.57) | L3MBTL1LMNAPTGESTDP1ATM | |
| SCHEMBL2236717 | 0.76 | ALDH1A1 (0.53) | L3MBTL1PTGESTDP1ATMNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102186811-B | Process for producing bisoxazolinone compound and intermediate thereof | SUMITOMO CO LTD | 2013-07-24 | — | — | CN | disclosed |
| US-8299264-B2 | Method for producing oxadiazolinone compound and intermediate thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-10-30 | — | — | US | disclosed |
| CN-102186811-A | Process for producing bisoxazolinone compound and intermediate thereof | SUMITOMO CHEMICAL CO | 2011-09-14 | — | — | CN | disclosed |
| US-20110207936-A1 | METHOD FOR PRODUCING OXADIAZOLINONE COMPOUND AND INTERMEDIATE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-08-25 | — | — | US | disclosed |
| EP-2357167-A1 | METHOD FOR PRODUCING OXADIAZOLINONE COMPOUND AND INTERMEDIATE THEREOF | Sumitomo Chemical Company, Limited (JP) | 2011-08-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207936-A1 | METHOD FOR PRODUCING OXADIAZOLINONE COMPOUND AND INTERMEDIATE THEREOF | AHR, CYP1B1, AR | L3MBTL1 3727/4885LMNA 2407/4885PTGES 1865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.